文献速递脊柱关节炎其他结缔组织病

银屑病或银屑病关节炎患者启动乌司奴单抗与其他生物制剂后严重感染住院风险比较

Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-07-08

这项多数据库队列研究纳入2009至2018年间启动阿达木单抗、阿普斯特、 certolizumab、依那西普、golimumab、ixekizumab、secukinumab或乌司奴单抗的银屑病或银屑病关节炎患者,比较严重感染住院风险。经倾向评分精细分层加权和荟萃分析,与乌司奴单抗相比,其他生物制剂和阿普斯特与严重感染住院风险升高相关。

要点

  • 与乌司奴单抗相比,阿达木单抗、依那西普、secukinumab、阿普斯特严重感染住院风险升高。
  • 英夫利西单抗和ixekizumab与严重感染住院风险升高关联更强。
  • 选择治疗方案时应考虑不同生物制剂和阿普斯特的严重感染安全性差异。

核心结论

  • 在银屑病或银屑病关节炎患者中,与乌司奴单抗相比,其他生物制剂和阿普斯特与严重感染住院风险升高1.4至3倍相关。

研究设计与样本

  • 多数据库队列研究,纳入2009至2018年间启动阿达木单抗、阿普斯特、certolizumab、依那西普、golimumab、ixekizumab、secukinumab或乌司奴单抗的银屑病或银屑病关节炎患者。
  • 共识别123,383例启动研究药物的银屑病或银屑病关节炎患者,总随访117,744人年。

主要发现

  • 随访期间发生1,514例严重感染,粗发病率为1.29/100人年。
  • 经倾向评分精细分层加权后,乌司奴单抗启动者的严重感染发病率范围为0.59至0.95/100人年。
  • 与乌司奴单抗相比,严重感染的合并加权HR(95%CI)为:阿达木单抗1.66(1.34-2.06),阿普斯特1.42(1.02-1.96),certolizumab 1.09(0.68-1.75),依那西普1.39(1.01-1.90),golimumab 1.74(1.00-3.03),英夫利西单抗2.92(1.80-4.72),ixekizumab 2.98(1.20-7.41),secukinumab 1.84(1.24-2.72)。

临床怎么用

  • 在为银屑病或银屑病关节炎患者选择生物制剂或阿普斯特时,应将严重感染住院风险差异纳入安全性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of serious infections requiring hospitalization in patients with psoriasis (PsO) or psoriatic arthritis (PsA) initiating ustekinumab versus other biologics or apremilast. METHODS: In this multi-database cohort study, we identified patients with PsO/PsA who initiated therapy with adalimumab, apremilast, certolizumab, etanercept, golimumab, ixekizumab, secukinumab, or ustekinumab between 2009 and 2018. The primary outcome measure was hospitalizations due to serious infections, which included bacterial, viral, or opportunistic infections. We estimated hazard ratios (HRs) comparing each study drug to ustekinumab after applying propensity score fine stratification weights for confounding control in each database. Database-specific weighted HRs were combined by meta-analysis. RESULTS: We identified 123,383 patients with PsO/PsA who initiated one of the study drugs. During a total of 117,744 person-years of follow-up, 1,514 serious infections occurred with a crude incidence of 1.29 per 100 person-years. After propensity score fine stratification and weighting, the incidence rates of serious infection among ustekinumab initiators ranged from 0.59 to 0.95 per 100 person-years. Compared with ustekinumab, the combined weighted HRs (95% confidence interval [95% CI]) for serious infections were 1.66 (95% CI 1.34-2.06) for adalimumab, 1.42 (95% CI 1.02-1.96) for apremilast, 1.09 (95% CI 0.68-1.75) for certolizumab, 1.39 (95% CI 1.01-1.90) for etanercept, 1.74 (95% CI 1.00-3.03) for golimumab, 2.92 (95% CI 1.80-4.72) for infliximab, 2.98 (95% CI 1.20-7.41) for ixekizumab, and 1.84 (95% CI 1.24-2.72) for secukinumab. CONCLUSION: Other biologics and apremilast were associated with a 1.4- to 3-times higher risk of hospitalization for serious infections in PsO/PsA patients when compared to ustekinumab; this finding should be considered in the safety profile of these therapies when selecting appropriate treatment regimens in patients with PsO/PsA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Jin Y, Lee H, Lee MP, et al. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2022. PMID: 33973371. doi:10.1002/acr.24630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。